- Home
- LTRN vs MREO Comparison
LTRN vs MREO Comparison
Compare LTRN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTRN | MREO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.8M | 49.4M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LTRN | MREO |
|---|---|---|
| Price | $3.98 | $0.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 187.5K | ★ 1.9M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.65 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.20 |
| 52 Week High | $5.74 | $2.37 |
Technical Indicators
Market Signals| Indicator | LTRN | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 59.48 |
| Support Level | $3.89 | $0.30 |
| Resistance Level | $4.20 | $0.36 |
| Average True Range (ATR) | 0.32 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 53.16 | 85.75 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).